Education
About Us
Working with TipRanks
Follow Us
Genfit SA (GNFTF)
OTHER OTC:GNFTF
GNFTF Stock Chart & Stats
$4.14
$0.10(2.91%)
At close: 4:00 PM EST
$4.14
$0.10(2.91%)
Day’s Range― - ―
52-Week Range$2.73 - $4.70
Previous CloseN/A
Volume2.00K
Average Volume (3M)0.00
Market Cap
$294.68M
Enterprise Value$193.70M
Total Cash (Recent Filing)$107.51M
Total Debt (Recent Filing)$138.91M
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Apr 09, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding50,024,750
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.12
Price to Book (P/B)2.57
Price to Sales (P/S)2.65
P/FCF Ratio12.50
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue4.29
Enterprise Value/Gross Profit4.61
Enterprise Value/Ebitda-8.33
Forecast
1Y Price Target
$9.87Price Target Upside138.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genfit News
GNFTF FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest stock price was $2.73 and its highest was $4.70 in the past 12 months.
What is Genfit SA’s market cap?
Genfit SA’s market cap is $294.68M.
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Apr 09, 2026 which is in 112 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Sep 22, 2025. The company reported -$0.235 earnings per share for the quarter, missing the consensus estimate of $1.204 by -$1.439.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Undervalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is 0.02.
How many shares outstanding does Genfit SA have?
Genfit SA has 50,024,750 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of -$0.235 in its last earnings report, missing expectations of $1.204. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in GNFTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genfit SA
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
GNFTF Stock 12 Month Forecast
Average Price Target
$9.87
▲(138.41% Upside)
Technical Analysis
Innate Pharma SA
―
Abivax SA
―
DBV Technologies
―
Nanobiotix
―
OSE Immunotherapeutics SA
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
― Other Institutional Investors
99.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---